Senseonics Stock Price, News & Analysis

Senseonics (NYSE American: SENS) announced a significant strategic shift in its Eversense 365 commercialization strategy. The company has signed a Memorandum of Understanding to take over all global commercialization and distribution from Ascensia Diabetes Care, effective January 1, 2026.

Key developments include the appointment of Brian Hansen as Chief Commercial Officer and an expanded debt facility up to $100 million with Hercules Capital to fund the commercial organization. The company expects 2025 global net revenue of $34-38 million and projects gross margin expansion to 50% in 2026, increasing to over 70% at scale.

For 2025, Senseonics anticipates doubling its global patient base, with gross margins between 32.5% and 37.5%. Cash used in operations is expected to be approximately $60 million.

Senseonics Holdings (NYSE American: SENS) reported Q2 2025 financial results, achieving $6.6 million in revenue, up 37% year-over-year, driven by a 79% increase in U.S. new patient starts. The company raised $77.8 million in total gross proceeds, including $57.5 million from a public offering and $20.3 million from Abbott.

Q2 net loss improved to $14.5 million ($0.02 per share) from $20.3 million in Q2 2024. The company expanded its DTC advertising campaign, completed provider transition to Eon Care, and entered a commercial agreement to integrate Sequel Med Tech's twiist™ AID system with Eversense 365.

For full-year 2025, Senseonics maintains guidance of $34-38 million in global net revenue, expecting to double its global patient base with gross margins between 32.5% and 37.5%.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term implantable continuous glucose monitoring systems for diabetes patients, has scheduled its second quarter 2025 earnings release and conference call for August 6, 2025.

The financial results will be released after market close, followed by a management conference call at 4:30 PM Eastern Time. Investors can access the call via phone (US/Canada: 1-800-225-9448, International: 1-203-518-9708, passcode: SENSQ2) or through a webcast available on the company's investor relations website.

Senseonics Holdings (NYSE: SENS) announced an upcoming analyst event on June 21, 2025, at 8:00am CT at the Marriot Marquis Chicago, coinciding with ADA 2025. The event will showcase their FDA-approved Eversense 365 Continuous Glucose Monitoring system for diabetes patients 18 and older. Key speakers include company management, Brian Hansen from Ascencia Diabetes Care discussing the commercial launch, and Gary Graf from Cotton-O'Neil discussing system experience and insertion procedures. Management will also address their partnership with Sequel for the twiist automated insulin delivery pump integration and future implantable CGM technology developments. The event will be available both in-person and virtually, concluding with a Q&A session.

Senseonics Holdings (NYSE: SENS) has successfully completed two capital raising initiatives: a public offering and a private placement. The public offering raised $57.5 million through the sale of 115 million shares at $0.50 per share, including the full exercise of underwriters' option for 15 million additional shares. Additionally, Abbott Laboratories participated in a private placement, acquiring 40.5 million shares (4.99% ownership) for $20.3 million.

The combined proceeds will fund the ongoing launch of Eversense 365, their implantable continuous glucose monitoring system for diabetes patients, pipeline product development, working capital, and general corporate purposes. The offering was managed by TD Cowen, Barclays, RBC Capital Markets, and Lake Street.

Senseonics Holdings (NYSE: SENS) has announced the pricing of a $50 million public offering of common stock, consisting of 100,000,000 shares priced at $0.50 per share. The company also granted underwriters a 30-day option to purchase up to an additional 15,000,000 shares. In a concurrent private placement, Abbott Laboratories will purchase shares at $0.50 per share, representing 4.99% of Senseonics' post-offering outstanding common stock.

The offering is expected to close on May 19, 2025, with TD Cowen and Barclays acting as joint book-running managers. The net proceeds will be used to fund the ongoing launch of Eversense 365 and pipeline product development, along with working capital and general corporate purposes.

Senseonics Holdings (NYSE: SENS) has announced a public offering of common stock aiming to raise $50 million, along with a concurrent private placement. The company will grant underwriters a 30-day option to purchase an additional 15% of the total shares offered. Abbott Laboratories has agreed to purchase up to $25 million of shares in a separate private placement at the public offering price.

The offering is being managed by TD Cowen and Barclays as joint book-running managers, with RBC Capital Markets and Lake Street as bookrunners. The proceeds will be used to fund the ongoing launch of Eversense 365, continue pipeline product development, and support working capital and general corporate purposes.

Senseonics Holdings (NYSE: SENS) reported Q1 2025 financial results with revenue of $6.3 million, representing a 24% year-over-year growth. Key highlights include a partnership with Sequel to integrate twiist™ automated insulin delivery system with Eversense® 365 CGM, targeting Q3 launch. The company secured CMS reimbursement for Eversense 365, effective January 2025. Q1 gross profit improved to $1.5 million, while net loss decreased to $14.3 million ($0.02 per share). Operating expenses decreased with SG&A at $7.7 million and R&D at $7.3 million. For full-year 2025, Senseonics expects global net revenue of $34-38 million, projecting to double its global patient base. The company anticipates gross margins between 25-30% and cash usage in operations of $50-60 million.

Senseonics Holdings, a pioneer in medical technology focusing on implantable continuous glucose monitoring (CGM) systems for diabetes patients, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss Q1 2025 performance. Investors can participate through multiple channels:

• Conference call: US/Canada: 1-800-343-4136
• International: 1-203-518-9843
• Passcode: SENSQ1
• Webcast: Available on www.senseonics.com under Investor Relations

The webcast will be archived on the company's website for future reference. Participants are advised to dial in 5-10 minutes before the start time.